2023-07-05 17:35:55 ET
- VBI Vaccines ( NASDAQ: VBIV ) is down ~3% in after-hours trading Wednesday after it announced an underwritten public offering and a registered direct offering of common shares and warrants.
- Raymond James is the sole book-runner.
- VBI ( VBIV ) said it intends to use the proceeds for commercialization of PreHevbrio [hepatitis B vaccine (recombinant)] and its manufacture; and pipeline development. Some will also be used for general corporate purposes.
- Seeking Alpha's Quant Rating views VBI ( VBIV ) as a strong sell.
For further details see:
VBI Vaccines down 3% after hours on public offering